Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

@article{Haluska2014PhaseID,
  title={Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.},
  author={Paul J Haluska and Michael E Menefee and Elizabeth R Plimack and Jonathan Rosenberg and Donald W. Northfelt and Theresa M Lavallee and Li Shi and Xiang-qing Yu and Patricia A. Burke and Jiaqi Huang and Jaye Viner and Jennifer McDevitt and Patricia M. LoRusso},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 18},
  pages={4747-57}
}
PURPOSE This phase I, multicenter, open-label, single-arm, dose-escalation, and dose-expansion study evaluated the safety, tolerability, and antitumor activity of MEDI-573 in adults with advanced solid tumors refractory to standard therapy or for which no standard therapy exists. EXPERIMENTAL DESIGN Patients received MEDI-573 in 1 of 5 cohorts (0.5, 1.5, 5, 10, or 15 mg/kg) dosed weekly or 1 of 2 cohorts (30 or 45 mg/kg) dosed every 3 weeks. Primary end points included the MEDI-573 safety… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Expression of insulin receptor isoformA and insulin-like growth factor-1 receptor in human acute myelogenous Clin Cancer Res

  • AE Wahner Hendrickson, P Haluska, PA Schneider, DA Loegering, KL Peterson, R Attar
  • Clinical Cancer Research
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…